AU2012258575B2 - Pirfenidone and anti-fibrotic therapy in selected patients - Google Patents

Pirfenidone and anti-fibrotic therapy in selected patients Download PDF

Info

Publication number
AU2012258575B2
AU2012258575B2 AU2012258575A AU2012258575A AU2012258575B2 AU 2012258575 B2 AU2012258575 B2 AU 2012258575B2 AU 2012258575 A AU2012258575 A AU 2012258575A AU 2012258575 A AU2012258575 A AU 2012258575A AU 2012258575 B2 AU2012258575 B2 AU 2012258575B2
Authority
AU
Australia
Prior art keywords
pirfenidone
fvc
receptor
limited
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012258575A
Other languages
English (en)
Other versions
AU2012258575A1 (en
Inventor
Williamson Ziegler Bradford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AU2012258575A1 publication Critical patent/AU2012258575A1/en
Application granted granted Critical
Publication of AU2012258575B2 publication Critical patent/AU2012258575B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012258575A 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients Ceased AU2012258575B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161489936P 2011-05-25 2011-05-25
US61/489,936 2011-05-25
US201161490057P 2011-05-26 2011-05-26
US61/490,057 2011-05-26
US201161523047P 2011-08-12 2011-08-12
US61/523,047 2011-08-12
US201161524961P 2011-08-18 2011-08-18
US61/524,961 2011-08-18
PCT/US2012/039538 WO2012162592A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Publications (2)

Publication Number Publication Date
AU2012258575A1 AU2012258575A1 (en) 2013-11-21
AU2012258575B2 true AU2012258575B2 (en) 2017-03-02

Family

ID=47217770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012258575A Ceased AU2012258575B2 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Country Status (11)

Country Link
US (1) US20150164874A1 (https=)
EP (1) EP2713732A4 (https=)
JP (1) JP6170040B2 (https=)
KR (1) KR20140022048A (https=)
AU (1) AU2012258575B2 (https=)
CA (1) CA2835438A1 (https=)
HK (1) HK1197159A1 (https=)
IL (1) IL229226A0 (https=)
MX (1) MX2013013752A (https=)
SG (1) SG195110A1 (https=)
WO (1) WO2012162592A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
JP2014507474A (ja) * 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
ES2764840T3 (es) * 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2016140714A1 (en) * 2015-03-05 2016-09-09 The General Hospital Corporation Novel compositions and uses of metformin agents
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
KR20200044066A (ko) * 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
WO2020236615A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Mps modified peptides and use thereof
CN112239507A (zh) * 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합
EP4117659A4 (en) * 2020-03-13 2024-04-03 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN114617890A (zh) * 2020-12-08 2022-06-14 四川夏派森医药科技有限公司 DH404在治疗SARS-CoV-2感染中的应用
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
AU2003244922A1 (en) * 2002-06-28 2004-01-19 The Administrators Of The Tulane Educational Fund 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2914170C (en) * 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
JP5587184B2 (ja) * 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders

Also Published As

Publication number Publication date
JP2014518880A (ja) 2014-08-07
NZ617415A (en) 2017-07-28
CA2835438A1 (en) 2012-11-29
KR20140022048A (ko) 2014-02-21
US20150164874A1 (en) 2015-06-18
EP2713732A1 (en) 2014-04-09
WO2012162592A1 (en) 2012-11-29
AU2012258575A1 (en) 2013-11-21
JP6170040B2 (ja) 2017-07-26
IL229226A0 (en) 2014-01-30
EP2713732A4 (en) 2014-12-03
SG195110A1 (en) 2013-12-30
MX2013013752A (es) 2014-08-01
HK1197159A1 (en) 2015-01-09

Similar Documents

Publication Publication Date Title
AU2012258575B2 (en) Pirfenidone and anti-fibrotic therapy in selected patients
JP6532878B2 (ja) 組合せ医薬
EP2285366B1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
JP2019532051A (ja) Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
TW201029652A (en) Combinations comprising methotrexate and DHODH inhibitors
AU2019402151B2 (en) Combinations of a HDM2-p53 interaction inhibitor and a BCL2 inhibitor and their use for treating cancer
US11746103B2 (en) ALK-5 inhibitors and uses thereof
JP2012526772A (ja) ホスホイノシチド３−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
WO2021216814A1 (en) Btk inhibitors to treat pulmonary distress in covid-19 patients
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
JP7565132B2 (ja) がんの治療又は予防用医薬
TW202517302A (zh) 穩定的、濃縮的放射性核種錯合物溶液
NZ617415B2 (en) Pirfenidone and anti-fibrotic therapy in selected patients
US20250177352A1 (en) Combination treatment for cancer
McGowan et al. Drug-Drug Interaction Guide: From HIV Prevention to Treatment
JP2023177335A (ja) がん治療のための併用療法
Gras Avapritinib. PDGFR-alpha and KIT mutant inhibitor, Treatment of gastrointestinal stromal tumor, Treatment of systemic mastocytosis
HK40112852A (zh) 癌的治疗或预防用药物
Heist Phase II trial of cabozantinib (XL184) in patients with advanced solid (non-breast
HK1240076B (zh) 联用药物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired